Gregory Fiore

Founder and Chief Executive Officer • Exacis Biotherapeutics

Dr. Fiore is a co-founder and is the President and Chief Executive Officer of Exacis. He is a pharmaceutical/biotechnology executive and entrepreneur and is a co-founder and former CEO of Sollis Therapeutics, where during his tenure as CEO he raised ~$50M in funding from State grants as well as strategic venture investors. He oversaw the regulatory strategy development and initiation of pivotal clinical trials for the Company’s lead compound.

Before this he provided C-level medical support as consultant and acting Chief Medical Officer for several early stage biotechnology companies through a consultancy he founded in 2014. Prior to that he was the first CMO of The Medicines Company (MDCO) and held a variety of leadership roles at MDCO, Merck and Abbott Laboratories after spending time as a management consultant at McKinsey and Company.

Dr. Fiore completed Internal Medicine internship and residency as well as received clinical Pulmonary / Critical Care training at Harvard Medical School following his graduation as class valedictorian with his MD degree from New York Medical College.

Dr. Fiore serves on several Medical and Business Advisory Committees / Boards.  He is on the Executive Board of the Institute of Neuromodulation (ION), the Scientific Advisory Board for Advera Health Analytics, the Business Advisory Board for the Advanced Group of Companies, and the Editorial Advisory Board of the journal Clinical Leader. He serves as an advisor to Fiore Healthcare Advisors and SSI Strategy as well as several biotechnology companies and previously served on the Board of Dubset Media Holdings and the Executive Committee for the Safety of Oral Anticoagulants (SOAR) Registry.

Also Speaking

Jennifer Collins

Principal, Apheresis and Infusion Specialist • Vertex Cell and Gene Therapies

Maia Hansen

Chief Operating Officer • Athersys

Jason B. Litten

Chief Medical Officer • Chimeric Therapeutics

Event Info


Post-Event Report

Download the post-event report for Advanced Therapies Week 2024.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.